Top

American Journal of Clinical Dermatology

Published in:

01-01-2000 | Guest Commentary

Denileukin Diftitox: A Viewpoint by Madeleine Duvic

Author: Madeleine Duvic, M.D.

Published in: American Journal of Clinical Dermatology | Issue 1/2000

Excerpt

Specific targeting of tumor cells has many advantages for the treatment of cancer, especially for cancers involving the expansion of clonal malignant cells from the immune system. Denileukin diftitox, a new recombinant fusion toxin, uses the interleukin-2 (IL-2) ligand to target activated T cells that express the high affinity IL-2 receptor and kills them with diphtheria toxin. The IL-2 receptor, preferentially expressed on the surface of malignant T cells is composed of 3 subunits of which CD25 is the α-receptor. …

Title: Denileukin Diftitox: A Viewpoint by Madeleine Duvic
Author: Madeleine Duvic, M.D.
Publication date: 01-01-2000
Publisher: Springer International Publishing
Published in: American Journal of Clinical Dermatology / Issue 1/2000
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI: https://doi.org/10.2165/00128071-200001010-00009

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Denileukin Diftitox: A Viewpoint by Madeleine Duvic

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2000

Management of Post-Acne Scarring

A Viewpoint by Brigitte Dréno

Identifying Drug Rashes

Wound Cleansing and Dressing

Onychomycosis

Optimal Management of Atopic Dermatitis